Home
About
Capabilities
R&D
Investors
News
Careers
中文
Home
About
Capabilities
R & D
Investors
News
Careers
Press Release
Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
Jul 31, 2025
Mabwell Announces IND Application Acceptance for CDH17-Targeting ADC 7MW4911 from Both NMPA and FDA
➞
Jul 14, 2025
Mabwell Enters into License and Commercialization Agreement with UNILAB to Launch Denosumab Biosimilars in the Philippines
➞
Jul 01, 2025
Mabwell Passes Colombian GMP Inspection with “zero deficiencies” Result for Its Denosumab Injections
➞
Jun 27, 2025
Mabwell Announces Novel Drug Technology License Agreement with Qilu Pharmaceutical for Albipagrastim alfa for Injection
➞
Jun 26, 2025
Mabwell Bioscience and Calico Life Sciences Announce Exclusive Licensing Agreement for Novel IL-11 Targeting Monoclonal Antibody
➞
Jun 04, 2025
Highlights in Poster Presentations of Mabwell at 2025 ASCO
➞
Jun 04, 2025
Highlights in Oral Presentation of Mabwell's 9MW2821 at 2025 ASCO
➞
May 29, 2025
Mabwell Receives NMPA Approval for Albipagrastim alfa for Injection (MAILISHENG)
➞
May 23, 2025
Mabwell Announces Clinical Data of Multiple ADCs to be presented at 2025 ASCO Annual Meeting
➞
Apr 30, 2025
Mabwell Releases 6 Study Results of Innovative Drugs and Platforms at the 2025 AACR Annual Meeting
➞
1
2
Next